Fig. 4
From: A pooled analysis of mesenchymal stem cell-based therapy for liver disease
Meta-analysis of patient subgroups. Red indicates significant improvement in the mesenchymal stem cell (MSC) group compared with the control group; blue indicates no significant improvement. Subgroup analyses at other time points and of other parameters could not be conducted because of an insufficient number of studies. ALB albumin, ALT alanine aminotransferase, B-MSC bone marrow-derived mesenchymal stem cell, CI confidence interval, MELD model for end-stage liver disease, nRCT nonrandomized controlled trial, RCT randomized controlled trial, TBiL total bilirubin, UC-MSC umbilical cord-derived mesenchymal stem cell